[go: up one dir, main page]

MA33601B1 - Molécules d'anticorps anti-gcc, compositions et procédés apparentés - Google Patents

Molécules d'anticorps anti-gcc, compositions et procédés apparentés

Info

Publication number
MA33601B1
MA33601B1 MA34712A MA34712A MA33601B1 MA 33601 B1 MA33601 B1 MA 33601B1 MA 34712 A MA34712 A MA 34712A MA 34712 A MA34712 A MA 34712A MA 33601 B1 MA33601 B1 MA 33601B1
Authority
MA
Morocco
Prior art keywords
antibodies
formulations
gcc
antibody molecules
associated methods
Prior art date
Application number
MA34712A
Other languages
Arabic (ar)
English (en)
Inventor
Theresa O'keefe
Shixin Qin
Samuel S Nam
Edward A Greenfield
John Babcook
Original Assignee
Millennium Pharm Inc
Amgen British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43900696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33601(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc, Amgen British Columbia filed Critical Millennium Pharm Inc
Publication of MA33601B1 publication Critical patent/MA33601B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Inorganic Chemistry (AREA)

Abstract

La présente invention concerne des anticorps et des fragments se liant aux antigènes d'anticorps qui se lient à gcc. Les anticorps se lient à un domaine extracellulaire de gcc et peuvent être internalisés. Dans certains modes de réalisation, les anticorps sont humanisés, chimériques ou humains. La présente invention concerne également des acides nucléiques et des vecteurs codant pour les anticorps ou des parties de ceux-ci, des cellules recombinantes qui contiennent les acides nucléiques, et des compositions qui comprennent les anticorps ou les fragments se liant aux antigènes. L'invention concerne également des procédés thérapeutiques et diagnostiques utilisant les anticorps et les fragments liant l'antigène fournis dans la présente invention.
MA34712A 2009-10-23 2012-03-21 Molécules d'anticorps anti-gcc, compositions et procédés apparentés MA33601B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25447409P 2009-10-23 2009-10-23
PCT/US2010/053686 WO2011050242A1 (fr) 2009-10-23 2010-10-22 Molécules d'anticorps anti-gcc, compositions et procédés apparentés

Publications (1)

Publication Number Publication Date
MA33601B1 true MA33601B1 (fr) 2012-09-01

Family

ID=43900696

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34712A MA33601B1 (fr) 2009-10-23 2012-03-21 Molécules d'anticorps anti-gcc, compositions et procédés apparentés

Country Status (32)

Country Link
US (3) US8785600B2 (fr)
EP (2) EP2490720B1 (fr)
JP (2) JP5925684B2 (fr)
KR (2) KR101834890B1 (fr)
CN (3) CN104447996A (fr)
AR (1) AR078751A1 (fr)
AU (1) AU2010310545C1 (fr)
BR (1) BR112012007523A2 (fr)
CA (2) CA3031851C (fr)
CL (1) CL2012000806A1 (fr)
CR (1) CR20120124A (fr)
DO (1) DOP2012000066A (fr)
EA (2) EA201792376A3 (fr)
EC (1) ECSP12011761A (fr)
ES (1) ES2788457T3 (fr)
GE (3) GEP20196956B (fr)
IL (3) IL218763A (fr)
IN (1) IN2012DN02604A (fr)
MA (1) MA33601B1 (fr)
MX (3) MX2012003198A (fr)
MY (1) MY173390A (fr)
NZ (2) NZ598791A (fr)
PE (1) PE20121542A1 (fr)
PH (2) PH12012500665B1 (fr)
PL (1) PL2490720T3 (fr)
SA (1) SA110310795B1 (fr)
SG (3) SG10202011656XA (fr)
TN (1) TN2012000122A1 (fr)
TW (2) TWI483736B (fr)
UA (1) UA108991C2 (fr)
WO (1) WO2011050242A1 (fr)
ZA (1) ZA201201944B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002051438A2 (fr) 2000-12-22 2002-07-04 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Utilisation de rgm et de ses modulateurs
CA2624562A1 (fr) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Domaines de liaison de proteines de la famille proteinique des molecules de guidage repulsif (rgm), fragments fonctionnels de ces domaines et leur utilisation
EP2033971A1 (fr) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Domaines de protéines recombinantes des protéines morphogénétiques osseuses (BMP) de la famille des Repulsive Guidance Molecule (RGM) et leurs fragments fonctionnels ainsi que leur utilisation
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
SG10202011656XA (en) 2009-10-23 2020-12-30 Millennium Pharm Inc Anti-gcc antibody molecules and related compositions and methods
DK2510001T3 (en) * 2009-12-08 2016-02-29 Abbvie Deutschland MONOCLONAL ANTIBODIES AGAINST RGM A PROTEIN USED TO TREAT DEGENERATION OF THE RETINAL NERVE FIBER LAYER
KR101844479B1 (ko) 2011-11-17 2018-04-03 삼성전자주식회사 항 ｃ-Ｍｅｔ 항체 및 그의 용도
IL305223A (en) 2012-01-27 2023-10-01 Abbvie Inc The composition and method for the diagnosis and treatment of diseases related to the degeneration of nerve cells
SG11201406855TA (en) 2012-04-27 2014-11-27 Millennium Pharm Inc Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
JP2016511257A (ja) * 2013-02-28 2016-04-14 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌の治療における抗ｇｃｃ抗体−薬物複合体及びｄｎａ損傷剤の投与
ES2996807T3 (en) * 2013-03-15 2025-02-13 Regeneron Pharma Biologically active molecules, conjugates thereof, and therapeutic uses
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
JP2015209384A (ja) * 2014-04-24 2015-11-24 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 医薬製剤
JP2019511462A (ja) * 2016-02-05 2019-04-25 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｇｃｃ標的化抗体−薬物コンジュゲート
US10654934B2 (en) 2016-04-01 2020-05-19 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
WO2017167217A1 (fr) 2016-04-01 2017-10-05 Innovative Cellular Therapeutics CO., LTD. Utilisation de cellules modifiées par un récepteur d'antigène chimérique pour traiter le cancer
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
JP7685735B2 (ja) 2016-12-02 2025-05-30 アンヘレス セラピューティクス インコーポレイテッド 合成免疫受容体およびその使用方法
KR101928079B1 (ko) 2016-12-12 2018-12-11 한화케미칼 주식회사 디시클로펜타디엔계 수지의 제조 방법 및 디시클로펜타디엔계 수지
CN116672463A (zh) * 2017-02-17 2023-09-01 浙江特瑞思药业股份有限公司 靶向cd20抗体偶联药物的制备方法、抗体偶联药物及其用途
CN108452319A (zh) * 2017-02-20 2018-08-28 浙江特瑞思药业股份有限公司 靶向cd20的抗体偶联药物制剂
AU2019236307A1 (en) * 2018-03-16 2020-10-22 Thomas Jefferson University Anti-GUCY2C chimeric antigen receptor compositions and methods
SG11202010934SA (en) * 2018-05-23 2020-12-30 Pfizer Antibodies specific for gucy2c and uses thereof
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
JP7604396B2 (ja) 2019-05-10 2024-12-23 武田薬品工業株式会社 抗体薬物複合体
WO2021076559A1 (fr) * 2019-10-14 2021-04-22 The Scripps Research Institute Anticorps humains largement neutralisants contre la région externe proximale-membranaire d'env du vih pour la conception et l'intervention vaccinales
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
WO2021205325A1 (fr) * 2020-04-08 2021-10-14 Pfizer Inc. Anticorps anti-gucy2c et leurs utilisations
US12043654B2 (en) * 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
EP4055176A4 (fr) * 2020-11-07 2024-04-17 Thomas Jefferson University Vaccins anti-gucy2c et vaccination
TW202237639A (zh) * 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
AU2022219373A1 (en) 2021-02-15 2023-08-24 Takeda Pharmaceutical Company Limited Cell therapy compositions and methods for modulating tgf-b signaling
KR102760955B1 (ko) * 2021-04-07 2025-02-03 주식회사 엘지화학 Gucy2c 결합 폴리펩타이드 및 그의 용도
CN115521379B (zh) * 2021-07-16 2023-12-22 南京吉盛澳玛生物医药有限公司 Pd-1抗体及其用途
KR20250075590A (ko) * 2022-09-28 2025-05-28 레전드 바이오테크 아일랜드 리미티드 Gcc를 표적으로 하는 항체 및 키메라 항원 수용체 및 이의 사용 방법
CN120187760A (zh) * 2022-11-23 2025-06-20 辐联科技香港有限公司 特异性结合gcc的抗体
CN116535514B (zh) * 2023-06-15 2024-02-02 上海斯丹赛生物技术有限公司 抗鸟苷酸环化酶c抗体及其在癌症治疗中的应用
WO2025153527A1 (fr) 2024-01-19 2025-07-24 Englmeier Ludwig Utilisation diagnostique d'immunoglobuline e
EP4588490A1 (fr) 2024-01-19 2025-07-23 Englmeier, Ludwig Utilisation diagnostique de l'immunoglobuline e

Family Cites Families (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US35500A (en) 1862-06-10 Improvement in dampers
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO1986005807A1 (fr) 1985-04-01 1986-10-09 Celltech Limited Lignee cellulaire de myelomes transformee et procede d'expression d'un gene codant un polypeptide eucaryotque employant cette lignee
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8800077D0 (en) 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
WO1989007142A1 (fr) 1988-02-05 1989-08-10 Morrison Sherie L Anticorps a region constante a modification de domaine
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
AU650629B2 (en) 1989-08-09 1994-06-30 Rhomed Incorporated Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
EP0542810A1 (fr) 1990-08-02 1993-05-26 B.R. Centre Limited Procedes de production de proteines presentant une fonction souhaitee
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
US5237051A (en) 1990-12-06 1993-08-17 Vanderbilt University Purified enterotoxin receptor protein
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0746609A4 (fr) 1991-12-17 1997-12-17 Genpharm Int Animaux transgeniques non humains capables de produire des anticorps heterologues
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
EP0552108B1 (fr) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Essai fluoro-immunologique impliquant un transfert d'énergie par phase-modulation
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
EP0592677B1 (fr) 1992-02-18 2001-11-07 Otsuka Kagaku Kabushiki Kaisha COMPOSE DE BêTA-LACTAME, COMPOSE DE CEPHEM, ET LEUR PRODUCTION
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP1589107B1 (fr) 1992-08-21 2009-12-23 Vrije Universiteit Brussel Immunoglobulines dépourvus de chaînes légères
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
ES2146648T3 (es) 1993-03-09 2000-08-16 Genzyme Corp Procedimiento de aislamiento de proteinas de la leche.
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
CA2163345A1 (fr) 1993-06-16 1994-12-22 Susan Adrienne Morgan Anticorps
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
ES2216004T3 (es) 1993-10-26 2004-10-16 Thomas Jefferson University Composiciones que se unen especificamente a celulas cancerosas colorectales y procedimientos de uso de las mismas.
US5879656A (en) 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US5601990A (en) 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
US7097839B1 (en) 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US5518888A (en) 1993-10-26 1996-05-21 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US6455251B1 (en) 1994-09-13 2002-09-24 Thomas Jefferson University Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
WO1997008320A1 (fr) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Banques de proteines/(poly)peptides
ATE234635T1 (de) 1995-12-22 2003-04-15 Bristol Myers Squibb Co Verzweigte hydrazongruppen enthaltende kuppler
WO1997042506A1 (fr) 1996-05-03 1997-11-13 Thomas Jefferson University Procedes et trousses de diagnostic et compositions permettant de diagnostiquer des tumeurs colorectales et leurs metastases
WO1997042220A1 (fr) 1996-05-03 1997-11-13 Thomas Jefferson University Vaccin contre le cancer recto-colique metastatique
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6340463B1 (en) 1996-08-14 2002-01-22 Vanderbilt University Identification of antigenic peptide sequences
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
GB9700154D0 (en) 1997-01-07 1997-02-26 Primapharma Ltd Peptides
CA2282504A1 (fr) 1997-02-25 1998-08-27 Jun-Ping Xu Isolement et analyse de la structure des depsipeptides cytostatiques lineaires et des cyclo-depsipeptides cytostatiques dolastatine 16, dolastatine 17, dolastatine 18
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
EP0983303B1 (fr) 1997-05-21 2006-03-08 Biovation Limited Procede de production de proteines non immunogenes
US6120995A (en) 1997-08-07 2000-09-19 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US6197582B1 (en) 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
CN1406138A (zh) 1998-11-03 2003-03-26 塞恩托科公司 活性持续时间被增加的修饰抗体和抗体片段
US8092514B1 (en) 1998-11-16 2012-01-10 Boston Scientific Scimed, Inc. Stretchable anti-buckling coiled-sheet stent
CA2342967A1 (fr) 1998-12-08 2000-06-15 Biovation Limited Modification de l'immunogenicite de proteines
US6132922A (en) 1999-01-06 2000-10-17 Advanced Color Technology, Inc. Liquid developer for electrophotographic printing apparatus
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
EP2270150B2 (fr) 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
WO2000075662A1 (fr) * 1999-06-09 2000-12-14 Ljl Biosystems, Inc. Essais uur la signalisation cellulaire
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
EP1242401B1 (fr) 1999-11-24 2006-12-27 Immunogen, Inc. Agents cytotoxiques comprenant des taxanes et leur utilisation therapeutique
FR2805994A1 (fr) 2000-03-10 2001-09-14 Agronomique Inst Nat Rech Methode de detection de la guanylyl cyclase-c et son utilisation pour le diagnostic des tumeurs colorectales metastatiques
JP2003535580A (ja) * 2000-03-27 2003-12-02 トーマス ジェファーソン ユニバーシティ 高特異性マーカー検出
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
DK1377314T3 (da) 2001-01-26 2011-12-12 Inhibitex Inc Monoklonale antistoffer mod CLFA-proteinet og fremgangsmåder til anvendelse i behandling eller forebyggelse af infektioner
CA2905585C (fr) 2001-03-29 2020-02-18 Synergy Pharmaceuticals, Inc. Agonistes recepteurs de guanylate cyclase destines au traitement ou a la prevention du cancer ou de polypes
US20040152868A1 (en) 2001-03-30 2004-08-05 Larsen Bjarne Due Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease
YU80903A (sh) * 2001-04-13 2006-05-25 Biogen Inc. Antitela vla-1
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
CA2763913C (fr) 2001-08-10 2014-10-28 Aberdeen University Domaines de liaison a l'antigene
EP1433793A4 (fr) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd Procede pour creer une banque d'anticorps de chameaux
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
DE60220719T2 (de) 2001-12-28 2008-03-06 Amgen Fremont Inc. Antikörper gegen das muc18-antigen
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20030186302A1 (en) * 2002-03-29 2003-10-02 Yixin Wang Colorectal cancer diagnostics
SI2357006T1 (sl) 2002-07-31 2016-01-29 Seattle Genetics, Inc. Konjugati zdravil in njihova uporaba za zdravljenje raka, avtoimunske bolezni ali infekcijske bolezni
US20040110933A1 (en) * 2002-09-13 2004-06-10 Dyax Corporation CD44-binding ligands
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US8206704B2 (en) 2003-02-10 2012-06-26 Thomas Jefferson University Use of GCC ligands
US20090005257A1 (en) * 2003-05-14 2009-01-01 Jespers Laurent S Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire
EP2457587A1 (fr) * 2003-06-27 2012-05-30 Amgen Fremont Inc. Anticorps dirigés vers les mutants de suppression de récepteur de facteur de croissance épidermique et utilisations associées
US7871610B2 (en) 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
JP4942643B2 (ja) 2004-03-02 2012-05-30 シアトル ジェネティックス， インコーポレイテッド 部分的に付加された抗体およびそれらの結合体化方法
CA2559870A1 (fr) 2004-04-07 2005-10-27 Genetech,Inc. Spectrometrie de masse de conjugues d'anticorps
RU2402548C2 (ru) 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
EP2722060A3 (fr) 2004-06-25 2015-01-07 Thomas Jefferson University Ligands C de guanylyl cyclase
EP3505191A1 (fr) 2004-11-12 2019-07-03 Seattle Genetics, Inc. Auristatines comportant une unité d'acide aminobenzoïque au niveau du n terminal
ZA200705695B (en) * 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
CA2647282A1 (fr) 2006-04-05 2007-10-11 Pfizer Products Inc. Polytherapie a base d'un anticorps anti-ctla4
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
EP2170930B3 (fr) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
CN101827609B (zh) * 2007-08-10 2014-03-12 里珍纳龙药品有限公司 抗人神经生长因子的高亲和力人抗体
DK2188306T3 (en) 2007-08-10 2016-08-22 Janssen Biotech Inc IMMUNOGLOBULIN CLUTCH FRAGMENTS AS DISEASE INDICATORS AND COMPOSITIONS FOR THE DETECTION AND BINDING OF SUCH
ES2599172T3 (es) 2007-10-19 2017-01-31 Seattle Genetics, Inc. Agentes de unión a CD19 y usos de éstos
US8426561B2 (en) 2007-11-27 2013-04-23 Francina C. Chahal Antibodies against a cancer-associated epitope of variant NFKBIB and uses thereof
ES2372236T3 (es) 2007-11-30 2012-01-17 Genentech, Inc. Polimorfismos de vegf y terapia anti-angiogénesis.
WO2009140436A2 (fr) 2008-05-13 2009-11-19 Thomas Jefferson University Rt-pct quantitative de la guanylyl cyclase c
CA2726913C (fr) 2008-06-04 2020-02-25 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
EP2321341B1 (fr) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
JP2012510295A (ja) 2008-12-03 2012-05-10 ベーリンガー インゲルハイム ファーマスーティカルズ アイエヌシー． グアニル酸シクラーゼ受容体に対する抗体
PT2881402T (pt) 2009-02-12 2017-08-23 Cell Signaling Technology Inc Expressão de ros mutante em cancro de fígado humano
WO2010096929A1 (fr) 2009-02-25 2010-09-02 Diagnocure Inc. Procédé de détection de métastase d'un cancer du tractus gastro-intestinal
WO2010104035A1 (fr) 2009-03-12 2010-09-16 学校法人近畿大学 Procédé permettant de prédire l'efficacité thérapeutique de la chimiothérapie sur le cancer du poumon non à petites cellules
WO2010147684A1 (fr) 2009-06-15 2010-12-23 Thomas Jefferson University Compositions et procédés d'activation de la guanylyl cyclase c
US20120251509A1 (en) 2009-10-22 2012-10-04 Waldman Scott A Cell-based anti-cancer compositions and methods of making and using the same
SG10202011656XA (en) 2009-10-23 2020-12-30 Millennium Pharm Inc Anti-gcc antibody molecules and related compositions and methods
JP2013534515A (ja) 2010-06-01 2013-09-05 モナシュ ユニバーシティ プロセシングされていない受容体型チロシンキナーゼｃ−ＭＥＴに対する抗体
CA2806447A1 (fr) 2010-08-13 2012-02-16 F. Hoffmann-La Roche Ag Utilisation de la neuropiline comme biomarqueur pour des traitements combines a base de bevacizumab
US20150086481A1 (en) * 2011-07-28 2015-03-26 Memorial Sloan-Kettering Cancer Center Diagnosis and treatment of parkinson's disease
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
SG11201406855TA (en) 2012-04-27 2014-11-27 Millennium Pharm Inc Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
JP2016511257A (ja) 2013-02-28 2016-04-14 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌の治療における抗ｇｃｃ抗体−薬物複合体及びｄｎａ損傷剤の投与
JP2017503763A (ja) 2013-12-03 2017-02-02 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｇｃｃ発現細胞を撮像するための化合物及び組成物
JP2019511462A (ja) 2016-02-05 2019-04-25 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｇｃｃ標的化抗体−薬物コンジュゲート
WO2017167217A1 (fr) 2016-04-01 2017-10-05 Innovative Cellular Therapeutics CO., LTD. Utilisation de cellules modifiées par un récepteur d'antigène chimérique pour traiter le cancer

Also Published As

Publication number Publication date
EP3520816B1 (fr) 2022-08-31
PH12012500665B1 (en) 2019-10-30
NZ598791A (en) 2014-05-30
GEP20166504B (en) 2016-06-27
US20180355062A1 (en) 2018-12-13
DOP2012000066A (es) 2013-04-15
EP2490720A1 (fr) 2012-08-29
TW201524517A (zh) 2015-07-01
TWI583394B (zh) 2017-05-21
CA2774032C (fr) 2019-03-26
KR101834890B1 (ko) 2018-04-20
SA110310795B1 (ar) 2014-07-14
ECSP12011761A (es) 2012-05-30
JP2013507968A (ja) 2013-03-07
EA201270365A1 (ru) 2012-09-28
BR112012007523A2 (pt) 2017-06-20
AU2010310545A1 (en) 2012-05-17
US10941211B2 (en) 2021-03-09
IL260285B (en) 2019-08-29
EP2490720A4 (fr) 2013-06-05
UA108991C2 (uk) 2015-07-10
US8785600B2 (en) 2014-07-22
WO2011050242A1 (fr) 2011-04-28
CA2774032A1 (fr) 2011-04-28
AU2010310545B2 (en) 2014-11-06
CL2012000806A1 (es) 2012-08-03
SG10202011656XA (en) 2020-12-30
IN2012DN02604A (fr) 2015-09-04
IL218763A0 (en) 2012-06-28
CN104447996A (zh) 2015-03-25
TW201132352A (en) 2011-10-01
IL247842B (en) 2018-06-28
MY173390A (en) 2020-01-22
EA201792376A3 (ru) 2018-08-31
TWI483736B (zh) 2015-05-11
SG10201407757XA (en) 2015-01-29
GEP20196956B (en) 2019-03-25
ES2788457T3 (es) 2020-10-21
AR078751A1 (es) 2011-11-30
CN110054692A (zh) 2019-07-26
AU2010310545A8 (en) 2012-10-11
TN2012000122A1 (en) 2013-09-19
PH12019500438A1 (en) 2020-07-20
IL218763A (en) 2016-10-31
PE20121542A1 (es) 2012-12-06
PL2490720T3 (pl) 2020-08-24
NZ623607A (en) 2016-07-29
KR20170123723A (ko) 2017-11-08
IL260285A (en) 2018-07-31
EP3520816A2 (fr) 2019-08-07
GEAP201813723A (en) 2018-11-26
EA201792376A2 (ru) 2018-03-30
KR20120128120A (ko) 2012-11-26
EA030827B1 (ru) 2018-10-31
US20110110936A1 (en) 2011-05-12
EP3520816A3 (fr) 2019-10-09
EP2490720B1 (fr) 2020-02-12
JP2016028603A (ja) 2016-03-03
MX366890B (es) 2019-07-30
CR20120124A (es) 2012-07-04
MX2019008956A (es) 2019-09-13
PH12012500665A1 (en) 2012-10-29
US20140322233A1 (en) 2014-10-30
CA3031851A1 (fr) 2011-04-28
JP5925684B2 (ja) 2016-05-25
CN102573908A (zh) 2012-07-11
AU2010310545C1 (en) 2015-04-30
ZA201201944B (en) 2013-05-29
CN102573908B (zh) 2014-12-17
SG179567A1 (en) 2012-05-30
CA3031851C (fr) 2020-07-07
MX2012003198A (es) 2012-06-12

Similar Documents

Publication Publication Date Title
MA33601B1 (fr) Molécules d'anticorps anti-gcc, compositions et procédés apparentés
WO2006104677A3 (fr) Anticorps se liant a ov064 et leurs methodes d'utilisation
MA34763B1 (fr) Anticorps anti-cd38
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
UA109633C2 (uk) Антитіло людини проти тканинного фактора
MA42542B1 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
UA102667C2 (uk) Людське нейтралізуюче антитіло проти в7rp1
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
EA200800812A1 (ru) Композиции антитела против cd3
EA201100694A1 (ru) Антитело к cd38 человека и его применение
CR10656A (es) Proteinas de union a interleuquina-13
MY153893A (en) Antibodies against human il17 and uses thereof
EA200870050A1 (ru) Анти-il-17-антитела
UY32949A (es) Proteínas de unión a il-1
PE20121552A1 (es) Anticuerpos monoclonales anti cea humanizados de afinidad madura
MY150531A (en) Anti-cd79b antibodies and immunoconjugates and methods of use
PE20140231A1 (es) Proteinas de union a antigeno contra proproteina converstasa subtilisina/kexina tipo 9 (pcsk9)
EA201070596A1 (ru) Гуманизированные антитела против tl1a
EA200870274A1 (ru) ПЕПТИДЫ, БЛОКИРУЮЩИЕ СВЯЗЫВАНИЕ IgG C FcRn
UA105760C2 (uk) Антитіло проти bst2
GEP20115226B (en) P-cadherin antibodies
WO2009135861A3 (fr) Anticorps humanisés contre l'interféron-alpha humain
MA33194B1 (fr) Anticorps humanisés ayant une activité antitumorale
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
WO2003106478A3 (fr) Anticorps se liant a l'integrine alphae